123i ibzm - a radiopharmaceutical containing the dopamine d2/d3 receptor agonist iodobenzamide (ibzm) labeled with the radionuclide iodine I 123 with dopamine receptor binding and radioisotopic activities. Upon administration, iodine I 123 iodobenzamide binds to dopamine d2/d3 receptors; subsequently, tissues expressing these receptors can be visualized using single photon emission computed tomography (spect). Dopamine receptors are a class of metabotropic g protein coupled receptors found in the central nervous system (cns) and neuroendocrine tumors such as pheochromocytoma and paraganglioma.
Up to date info
Latest research - 123i ibzm
Source: Data courtesy of the U.S. National Library of Medicine. Since the data might have changed, please query MeSH on 123i ibzm for any updates.